MALDI-FTICR-MSI检测吡非尼酮在肺纤维化中的药物代谢反应
该概念验证研究采用高分辨率MALDI-FTICR-MSI技术,在小鼠实验性纤维化模型和IPF患者肺组织中同时检测、可视化和定量内源及外源代谢物,评估吡非尼酮治疗对代谢物水平的影响。代谢通路分析和内源代谢物定量显示,吡非尼酮治疗恢复IPF组织的氧化还原失衡和糖酵解,下调抗坏血酸和醛糖酸代谢,可能原位调节胶原加工。
要点
- MALDI-FTICR-MSI可原位检测肺纤维化中内源和外源代谢物。
- 吡非尼酮恢复IPF组织氧化还原失衡和糖酵解。
- 吡非尼酮下调抗坏血酸和醛糖酸代谢,可能调节胶原加工。
核心结论
- 吡非尼酮治疗可恢复IPF组织的氧化还原失衡和糖酵解,并下调抗坏血酸和醛糖酸代谢。
- 高分辨率MALDI-FTICR-MSI适用于解析吡非尼酮的治疗效应。
研究设计与样本
- 概念验证研究,使用高分辨率定量MALDI-FTICR-MSI技术。
- 研究对象为实验性纤维化小鼠和IPF患者肺组织。
主要发现
- 吡非尼酮治疗恢复IPF组织的氧化还原失衡和糖酵解。
- 吡非尼酮下调抗坏血酸和醛糖酸代谢,可能原位调节胶原加工。
- 在纤维化中检测到代谢通路的特定改变,吡非尼酮治疗后出现代谢重校准。
临床怎么用
- MALDI-FTICR-MSI可用于解读吡非尼酮在肺纤维化中的治疗效应。
- 代谢改变分析可能有助于改进现有IPF治疗。
局限性
- 研究为初步分析,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic pulmonary fibrosis (IPF) is a fatal condition that reduces life expectancy and shows a limited response to available therapies. Pirfenidone has been approved for treatment of IPF, but little is known about the distinct metabolic changes that occur in the lung upon pirfenidone administration.Here, we performed a proof-of-concept study using high-resolution quantitative matrix-assisted laser desorption/ionisation Fourier-transform ion cyclotron resonance mass spectrometry imaging (MALDI-FTICR-MSI) to simultaneously detect, visualise and quantify in situ endogenous and exogenous metabolites in lungs of mice subjected to experimental fibrosis and human patients with IPF, and to assess the effect of pirfenidone treatment on metabolite levels.Metabolic pathway analysis and endogenous metabolite quantification revealed that pirfenidone treatment restores redox imbalance and glycolysis in IPF tissues, and downregulates ascorbate and aldarate metabolism, thereby likely contributing to in situ modulation of collagen processing. As such, we detected specific alterations in metabolite pathways in fibrosis and, importantly, metabolic recalibration following pirfenidone treatment.Together, these results highlight the suitability of high-resolution MALDI-FTICR-MSI for deciphering the therapeutic effects of pirfenidone and provide a preliminary analysis of the metabolic changes that occur during pirfenidone treatment in vivo These data may therefore contribute to improvement of currently available therapies for IPF.
引用
- Sun N, Fernandez IE, Wei M, et al. Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI. Eur Respir J. 2018. PMID: 30072508. doi:10.1183/13993003.02314-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。